Fenster schließen  |  Fenster drucken


Kursziel : 6$

Canaccord Genuity maintains a 'Buy' on Cytokinetics (NASDAQ: CYTK), PT $6.

Canaccord analyst says, "CK357 Phase 2 ALS efficacy data shows promise of real clinical benefit in ALS. We think CK357 has a strong mechanistic rationale in ALS and muscle-wasting diseases, and very promising new Phase 2 efficacy data. We think CYTK’s partner Amgen will continue to advance Phase 2 omecamtiv in heart failure trials in 2011. Our $6 price target is based on a pNPV analysis."

For more ratings news on Cytokinetics click here and for the rating history of Cytokinetics click here.

Shares of Cytokinetics closed at $2.93 yesterday, with a 52 week range of $2.03-$3.80.
aus der Diskussion: ALS - Biotech machts möglich?
Autor (Datum des Eintrages): Karl79  (13.12.10 17:52:55)
Beitrag: 2 von 9 (ID:40701965)
Alle Angaben ohne Gewähr © wallstreet:online